Psychopharmacology in the elderly person with cardiovascular disease

Annals of Long-Term Care

Volumn 14, Issue 5, 2006, Pages 34-45

  Leigh Pemberton, Richard A ^a   Von Moltke, Lisa L ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; AMITRIPTYLINE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CITALOPRAM; CLARITHROMYCIN; CLONIDINE; DROPERIDOL; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; METHYLDOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NIFEDIPINE; PAROXETINE; RESERPINE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGITATION; AKATHISIA; ANTICHOLINERGIC EFFECT; ATAXIA; BRADYCARDIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; DELIRIUM; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART BLOCK; HEART DEATH; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSIVE CRISIS; MEMORY DISORDER; META ANALYSIS; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; PSYCHOSIS; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; SYSTEMATIC REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 33646937774     PISSN: 15247929     EISSN: 15247929     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Black H. Risk stratification of older patients. Am J Hypertens 2002;15 (7 Pt 2):77S-81S.
2. Krishnan KR, Delong M, Kraemer H, et al. Comorbidity of depression with other medical diseases in the elderly. Biol Psychiatry 2002;52:559-588.
3. Kenny RA. Syncope in the elderly: Diagnosis, evaluation, and treatment. J Cardiovasc Electrophysiol 2003;14 (suppl 9):S74-S77.
4. Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health: Research agenda for the next 2 decades. Arch Gen Psychiatry 1999;56:848-853.
5. Unutzer J. Diagnosis and treatment of older adults with depression in primary care. Biol Psychiatry 2002;52:285-292.
6. Lapid M, Rummans TA. Evaluation and management of geriatric depression in primary care. Mayo Clin Proc 2003;78:1423-1429.
7. Alexopoulos GS, Vrontou C, Kakuma T, et al. Disability in geriatric depression. Am J Psychiatry 1996;153:877-885.
8. Unutzer J, Patrick DL, Diehr P, et al. Quality adjusted life years in older adults with depressive symptoms and chronic medical disorders. Int Psychogeriatr 2000;12:15-33.
9. Glassman AH, Rodriguez AI, Shapiro PA. The use of antidepressant drugs in patients with heart disease. J Clin Psychiatry 1998;59 (suppl 10):16-21.
10. von Moltke LL, Abernathy DR, Greenblatt DJ. Kinetics and dynamics of psychotropic drugs in the elderly. In: Salzman C, ed. Clinical Geriatric Psychopharmacology, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:87-114.
11. Alexopoulos G. Mood disorders. In: Sadock BJ SV, ed. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:3060-3068.
12. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 2002;287:337-344.
13. Ali Raza AJ, Movahed A. Use of cardiovascular medications in the elderly. Int J Cardiol 2002;85:203-215.
14. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: Drug disposition in old age. N Engl J Med 1982;306:1081-1088.
15. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Psychotropic drug metabolism in old age: Principles and problems of assessment. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, Ltd.; 1995:1461-1469.
16. Vestal RE. Aging and pharmacology. Cancer 1997;80:1302-1310.
17. Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301.
18. Turnheim K. Drug therapy in the elderly. Exp Gerontol 2004;39:1731-1738.
19. Shulman RW, Ozdemir V. Psychotropic medications and cytochrome P450 2D6: Pharmacokinetic considerations in the elderly. Can J Psychiatry 1997;42(suppl 1):4S-9S.
20. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999;19 (5 suppl 1):23S-35S.
21. Brown CS, Farmer RG, Soberman JE, Eichner SF. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet 2004;43:33-56.
22. Richelson E. Pharmacokinetic interactions of antidepressants. J Clin Psychiatry 1998;59 (suppl 10):22-26.
23. Shader RI, von Moltke LL, Schmider J, et al. The clinician and drug interactions-an update. J Clin Psychopharmacol 1996;16:197-201.
24. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4:281-97.
25. Zalma A, von Moltke LL, Granda BW, et al. In vitro metabolism of trazodone by CYP3A: Inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry 2000;47:655-61.
26. Bennett WM. Geriatric pharmacokinetics and the kidney. Am J Kidney Dis 1990;16:283-288.
27. Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging 1998;13:357-379.
28. Klotz U. Effect of age on pharmacokinetics and pharmacodynamics in man. Int J Clin Pharmacol Ther 1998;36:581-585.
29. De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview. Drug Saf 2002;25:263-286.
30. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135-141.
31. Gareri P, Stilo G, Bevacqua I, et al. Antidepressant drugs in the elderly. Gen Pharmacol 1998;30:465-475.
32. Ariyo AA, Haan M, Tangen CM, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 2000;102:1773-1779.
33. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: Impact on 6-month survival. JAMA 1993;270:1819-1825. Erratum in: JAMA 1994;271:1082.
34. Lesperance F, Frasure-Smith N, Juneau M, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000;160:1354-1360.
35. Lesperance F, Frasure-Smith N, Taljic M. Major depression before and after myocardial infarction: Its nature and consequences. Psychosom Med 1996;58:99-110.
36. Freedland KE, Carney RM, Scala JA. The prevalence of depression and dysthymia in patients with congestive heart failure. Psychosom Med 1995;57:62.
37. Freedland KE, Carney RM, Lustman PJ, et al. Major depression in coronary artery disease patients with versus without a prior history of depression. Psychosom Med 1992;54:416-421.
38. Koenig H. Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry 1998;20:29-43.
39. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 1997;102:54-59.
40. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns? Curr Pharm Des 2004;10:2463-2475.
41. Mann JJ. The medical management of depression. N Engl J Med 2005;353:1819-1834.
42. von Moltke LL, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications. Clin Pharmacokinet 1993;24:141-160.
43. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 2003;23:58-77.
44. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients. Risk/benefit reconsidered. JAMA 1993;269:2673-2675.
45. Glassman AH, Johnson LL, Giardina EGV, et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983;250:1997-2001.
46. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-1372.
47. Mulsant BH, Alexopoulos GS, Reynolds CF, et al; PROSPECT Study Group. Pharmacological treatment of depression in older primary care patients: The PROSPECT algorithm. Int J Geriatr Psychiatry 2001;16:585-592.
48. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998;155:660-665.
49. Cherin P, Colvez A, Deville de Periere G, Sereni D. Risk of syncope in the elderly and consumption of drugs: A case-control study. J Clin Epidemiol 1997;50:313-320.
50. Hay DP, Rodriguez MM, Franson KL. Treatment of depression in late life. Clin Geriatr Med 1998;14:33-46.
51. Schmider J, von Moltke LL, Shader RI, et al. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. Drug Metab Rev 1999;31:545-560.
52. Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: A practical review. J Psychosom Res 2000;48:379-391.
53. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P4503A substrates. Clin Pharmacokinet 2005;44:33-60.
54. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894-1898.
55. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry 1999;60 (suppl 8):29-41.
56. Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005;293:2462.
57. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized, placebo-controlled trials. JAMA 2005;294:1934-1943.
58. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-1167.
59. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of controversial vs atypical antipsychotic medications. N Engl J Med 2005;353:2335-2341.
60. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000;23:215-228.
61. Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab Dispos 1999;27:1078-1084.
62. Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly: Avoiding its onset. Drug Saf 1997;17:105-118.
63. Timell A. Thioridazine: Re-evaluating the risk/benefit equation. Ann Clin Psychiatry 2000;12:147-151.
64. Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry 2002;63 (Suppl 9):12-17.
65. Mehtonen OP, Aranko K, Malkonen L, Vapaatalo H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991;84:58-64.
66. Neil W, Curran S, Wattis J. Antipsychotic prescribing in older people. Age Ageing 2003;32:475-483.
67. Finkel S. Pharmacology of antipsychotics in the elderly: A focus on atypicals. J Am Geriatr Soc 2004;52 (suppl 12):S258-S265.
68. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-1845.
69. Barnes TRE, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl 1999;(38):34-43.
70. Madhusoodanan S, Brenner R, Cohen CI. Risperidone for elderly patients with schizophrenia or schizoaffective disorder. Psychiatric Annals 1999;30:175-180.
71. Yeung PP, Tariot PN, Schneider LS, et al. Quetiapine for elderly patients with psychotic disorders. Psychiatric Annals 2000;30:197-201.
72. Masand P. Clinical effectiveness of atypical antipsychotics in elderly patients with psychosis. Eur Neuropsychopharmacol 2004;14 (suppl 4):S461-S469.
73. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J Psychiatry 2003;160:290-296.
74. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: Metabolic outcomes after 1 year. J Clin Psychiatry 2002;63:425-433.
75. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study. BMJ 2002;325:243.
76. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39.
77. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345.
78. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841-852.
79. Koller EA, Cross JT, Doraiswamy PM, Schneider B. Risperidone-associated diabetes mellitus: A pharmacovigilance study. Pharmacotherapy 2003;23:735-744.
80. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001;111:716-723.
81. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566.
82. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 2005;293:596-608.
83. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004;161:1113-1115.
84. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. BMJ 2005;330:445.
85. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22:419-423.
86. Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 1999;19:494-499.
87. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9.
88. Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry 2004;65 (Suppl 2):5-104.